Equities Analysts Offer Predictions for RYTM FY2025 Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Stock analysts at HC Wainwright boosted their FY2025 earnings estimates for Rhythm Pharmaceuticals in a research note issued to investors on Tuesday, January 20th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($3.10) per share for the year, up from their prior estimate of ($3.13). HC Wainwright currently has a “Buy” rating and a $125.00 target price on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q4 2025 earnings at ($0.74) EPS, Q4 2026 earnings at ($0.29) EPS and FY2026 earnings at ($1.98) EPS.

A number of other brokerages also recently issued reports on RYTM. Wall Street Zen downgraded Rhythm Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. UBS Group reiterated a “buy” rating on shares of Rhythm Pharmaceuticals in a research report on Wednesday, December 17th. Guggenheim boosted their price objective on Rhythm Pharmaceuticals from $120.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Citizens Jmp raised their target price on shares of Rhythm Pharmaceuticals from $141.00 to $167.00 and gave the company a “market outperform” rating in a research note on Friday, December 12th. Finally, Oppenheimer cut shares of Rhythm Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Rhythm Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $131.29.

Rhythm Pharmaceuticals Price Performance

RYTM opened at $105.95 on Thursday. The company has a fifty day moving average price of $106.17 and a 200-day moving average price of $100.79. The firm has a market capitalization of $7.07 billion, a P/E ratio of -34.18 and a beta of 2.00. Rhythm Pharmaceuticals has a one year low of $45.90 and a one year high of $122.20.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.10). Rhythm Pharmaceuticals had a negative net margin of 110.32% and a negative return on equity of 433.21%. The firm had revenue of $51.30 million for the quarter, compared to analysts’ expectations of $50.71 million.

Insiders Place Their Bets

In other Rhythm Pharmaceuticals news, insider Joseph Shulman sold 9,748 shares of Rhythm Pharmaceuticals stock in a transaction dated Thursday, October 30th. The shares were sold at an average price of $115.24, for a total transaction of $1,123,359.52. Following the completion of the sale, the insider directly owned 8,509 shares in the company, valued at $980,577.16. This trade represents a 53.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Pamela J. Cramer sold 3,350 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $111.00, for a total transaction of $371,850.00. Following the completion of the sale, the insider directly owned 20,814 shares in the company, valued at $2,310,354. This trade represents a 13.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 15,913 shares of company stock valued at $1,818,963. Company insiders own 6.10% of the company’s stock.

Institutional Trading of Rhythm Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Rhythm Pharmaceuticals by 4.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,568 shares of the company’s stock valued at $259,000 after buying an additional 110 shares during the last quarter. Captrust Financial Advisors increased its holdings in shares of Rhythm Pharmaceuticals by 0.7% in the 2nd quarter. Captrust Financial Advisors now owns 17,471 shares of the company’s stock valued at $1,104,000 after acquiring an additional 114 shares during the period. GAMMA Investing LLC raised its position in Rhythm Pharmaceuticals by 48.6% in the 4th quarter. GAMMA Investing LLC now owns 361 shares of the company’s stock valued at $39,000 after purchasing an additional 118 shares during the last quarter. Smartleaf Asset Management LLC raised its position in Rhythm Pharmaceuticals by 97.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock valued at $29,000 after purchasing an additional 141 shares during the last quarter. Finally, Optiver Holding B.V. boosted its stake in Rhythm Pharmaceuticals by 65.2% during the 3rd quarter. Optiver Holding B.V. now owns 365 shares of the company’s stock worth $37,000 after purchasing an additional 144 shares during the period.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.